Nimodipine · Nimotop, Nymalize

What is Nimodipine?

Nimodipine is a dihydropyridine calcium channel blocker that inhibits calcium ion entry into vascular smooth muscle cells during depolarization, reducing vascular smooth muscle contraction. It acts more strongly on cerebral arteries because it is lipophilic and crosses the blood-brain barrier. It is studied in aneurysmal subarachnoid hemorrhage.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Nimotop, Nymalize, NSC-758476

Drug type

Small molecule

Targets

L-type voltage-gated calcium channel, P-glycoprotein (ABCB1) (secondary target)

Mechanism

Inhibitor of L-type voltage-gated calcium channel

Pathways

calcium ion influx into smooth muscle cells, vascular smooth muscle contraction

Therapy area

Cardiovascular, Neurology

Developer

Bayer Pharms

In trials of

GRCE

FDA status

Approved as Nimotop, Nymalize (December 28, 1988), NDA018869 · FDA label

UNII

57WA9QZ5WH

✅ FDA-approved uses

• Subarachnoid hemorrhage (Nymalize)

From the indications section of the FDA label (version of Aug 30, 2024). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Aneurysmal Subarachnoid Hemorrhage (aSAH)

Sources

• FDA label (DailyMed)
• FDA label Nymalize (2024-08-30), indications
• NCI Thesaurus

Updated Oct 11, 2026.